23:31 , Jul 16, 2019 |  BC Extra  |  Company News

Genentech adds three discovery partnerships to build out pipeline

Through a trio of deals with Convelo, Skyhawk and Sosei Heptares announced Tuesday, Genentech is adding programs that could refresh its early stage neurology pipeline, as well as its oncology and other early R&D. Global...
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
13:53 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting IRAK1 or its activator PIN1 could help treat radiotherapy-resistant, p53-mutant head and neck cancers and other cancers. In patients with...
20:31 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting PIN1 could help treat pancreatic ductal adenocarcinoma (PDAC). In patients, PIN1 levels were higher in tumor samples than in adjacent normal tissue samples...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
21:43 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Emixustat: Ph IIa started

Kubota’s Acucela Inc. subsidiary began a blinded, U.S. Phase IIa trial to evaluate 2.5, 5 and 10 mg oral emixustat once daily for 1 month in about 30 patients. Kubota Pharmaceutical Holdings Co. Ltd. (Tokyo:4596),...
22:35 , Dec 1, 2016 |  BC Innovations  |  Product R&D

De-stressing about NASH

With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders. The...
23:02 , Nov 17, 2016 |  BC Innovations  |  Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...